Shares of Celcuity Inc. (NASDAQ:CELC - Get Free Report) have received a consensus rating of "Buy" from the seven brokerages that are covering the stock, MarketBeat.com reports. Six analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $29.17.
A number of brokerages recently weighed in on CELC. Needham & Company LLC reissued a "buy" rating and issued a $23.00 price target on shares of Celcuity in a report on Friday, November 15th. HC Wainwright restated a "buy" rating and issued a $27.00 price objective on shares of Celcuity in a research report on Friday, November 15th. Finally, Stifel Nicolaus upped their target price on Celcuity from $39.00 to $42.00 and gave the stock a "buy" rating in a research note on Monday, October 7th.
Check Out Our Latest Report on CELC
Celcuity Stock Performance
Shares of Celcuity stock traded down $0.32 during mid-day trading on Tuesday, hitting $10.53. 303,694 shares of the stock were exchanged, compared to its average volume of 360,687. Celcuity has a 12 month low of $10.35 and a 12 month high of $22.19. The company has a 50-day simple moving average of $13.16 and a 200 day simple moving average of $15.12. The company has a market capitalization of $390.98 million, a P/E ratio of -4.03 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35.
Institutional Trading of Celcuity
Several hedge funds have recently added to or reduced their stakes in CELC. nVerses Capital LLC purchased a new position in shares of Celcuity in the third quarter worth $33,000. Prospera Private Wealth LLC purchased a new position in Celcuity during the third quarter valued at $35,000. Values First Advisors Inc. purchased a new stake in Celcuity in the third quarter worth about $86,000. Quest Partners LLC boosted its position in shares of Celcuity by 31.3% in the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company's stock worth $95,000 after purchasing an additional 1,379 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new stake in shares of Celcuity in the third quarter worth $119,000. 63.33% of the stock is owned by institutional investors.
About Celcuity
(
Get Free ReportCelcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.
Further Reading
Before you consider Celcuity, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.
While Celcuity currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
